Abstract: A method for aromatization of light alkanes, comprising: subjecting the light alkanes to dehydroaromatization reaction in the presence of aromatization catalysts including carriers and metal active components supported on the carriers, the metal active components include platinum, the carriers include zeolites and binders, and at least 80 wt. % of the metal active components are distributed on the zeolites. The method of the present disclosure may increase yield of the target product—aromatic hydrocarbons, and the regenerated catalyst can still maintain high catalytic performance. In addition, the method of the present disclosure can meet the requirements of industrial applications.

Abstract: In an aspect, the present disclosure provides a method for the oxidative coupling of methane to generate hydrocarbon compounds containing at least two carbon atoms (C2+ compounds). The method can include mixing a first gas stream comprising methane with a second gas stream comprising oxygen to form a third gas stream comprising methane and oxygen and performing an oxidative coupling of methane (OCM) reaction using the third gas stream to produce a product stream comprising one or more C2+ compounds.

Abstract: Integrated systems are provided for the production of higher hydrocarbon compositions, for example liquid hydrocarbon compositions, from methane using an oxidative coupling of methane system to convert methane to ethylene, followed by conversion of ethylene to selectable higher hydrocarbon products. Integrated systems and processes are provided that process methane through to these higher hydrocarbon products.

Abstract: Proposed is a process for producing ethylene wherein using a dehydrogenation of ethane a process gas containing at least ethane, ethylene and compounds having a lower boiling point than ethane and ethylene is formed, wherein using at least a part of the process gas a separation input is formed and subjected to a low-temperature separation (6) in which the separation input is cooled and in which one or more condensates are separated from the separation input, wherein the condensate(s) are at least partly subjected to a low-temperature rectification to obtain a gaseous first fraction and a liquid second fraction, wherein the gaseous first fraction contains at least the ethane and the ethylene in a lower proportion than in the separation input and the compounds having a lower boiling point than ethane and ethylene in a higher proportion than in the separation input.

Abstract: Provided is a method of separating and refining 1-butene with a high purity and a high yield from a raffinate-2 stream, and recovering the refined 1-butene while maximizing an energy saving rate by using a high efficiency distillation column installed with a separation wall.

Abstract: The present invention relates to an alphaolefin oligomer having a uniform structure and a method of preparing the same, in which the alphaolefin oligomer has a uniform molecular structure with a low branch ratio, thereby exhibiting improved thermal and oxidative stability, a long service life, low volatility, a low pour point and a high viscosity index.

Abstract: The invention provides a process for producing methanol, which process comprises contacting H2 and CO2 with a solid catalyst, at a temperature of from 200° C. to 300° C. and at a reactant pressure of from 150 bar to 500 bar, which reactant pressure is the sum of the partial pressures of the H2 and the CO2, wherein: the molar ratio of the H2 to the CO2 is x:1.0, wherein x is from 2.5 to 3.5; and the catalyst comprises: (i) a copper component which is Cu, CuO or Cu2O, or a mixture of two or three thereof, and (ii) ZnO, wherein the catalyst has a specific copper surface area of at least 10 m2/g-catalyst.

Abstract: Described herein is a process for preparing butane-1,4-diol by catalytic hydrogenation of butyne-1,4-diol in a reaction zone with hydrogen in the presence of a heterogeneous hydrogenation catalyst, in which the content of at least one gas selected from CO and CH4 in the offgas stream is measured and the content of the gas measured in the offgas stream is used for closed-loop control of the hydrogenation.

Abstract: Compounds and compositions are provided that inhibit histone deacylase activity and which expand renal progenitor cell populations and improve kidney function in a damaged kidney. Methods of use of the compounds and compositions are provided.

Abstract: The present invention relates to a process for the preparation of the compounds of formula II using a lanthanoid salt.

Abstract: The disclosure discloses a method for synthesizing 2,3,5,6-tetrafluoro-4-methoxymethyl benzyl alcohol from 1,4-bis(methoxymethyl)-2,3,5,6-tetratluorobenzene, belongings to the technical field of organic synthesis. 1,4-bis(methoxymethyl)-2,3-5,6-tetrafluorobenzene reacts in mixed solution consisting of sulfuric acid aqueous solution and organic carboxylic acid, the obtained mixture is subjected to ester group hydrolysis reaction in the presence of an inorganic base and then to hydroxyl methylation reaction, 2,3,5,6-tetrafluoro-4-methoxymethyl benzyl alcohol is finally obtained via separation and purification, and 1,4-bis(methoxymethyl)-2,3,5,6-tetrafluorobenzene is recovered. The disclosure not only realizes the resource utilization of low-value 1,4-bis(methoxymethyl)-2,3,5,6-tetrafluorobenzene, and meanwhile has the advantages of mild reaction conditions, simple operation, high synthesis yield, good product quality and the like. The disclosure has high social and economic values.

Abstract: The present invention generally relates to processes for converting acrylate esters or a derivative thereof to difluoropropionic acid or a derivative thereof. This process is generally performed using fluorine gas in a hydrofluorocarbon solvent.

Abstract: The present invention discloses a method for preparing a functionalized organic magnesium salt. The method includes completely dissolving organic acid in distilled water to form an organic acid aqueous solution, adding an inorganic magnesium salt into the organic acid aqueous solution, magnetically stirring for 1-5 h at 70-100° C., removing distilled water, and performing vacuum drying to obtain a white powdery solid which is a functionalized organic magnesium salt. An intrinsic flame-retardant PET composite material prepared by using the functionalized organic magnesium salt as a flame retardant not only achieves the compatibility between inorganic particles and a matrix, but also solves the problem of poor flame retardant performance of PET plastics in the existing production process.

Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of cytopathic diseases. Cytopathic diseases may be caused by a variety means such as viral infections like HIV and AIDS, or the development of neoplasms in a mammalian subject. The methods and compositions of the invention are effective for inhibiting de novo HIV infection, upregulating viral expression from latent provirus, inhibiting HIV-induced cytopathic effects, down regulating the HIV receptor, increasing Th1 cytokine expression, decreasing Th2 cytokine expression, increasing ERK phosphorylation, inducing apoptosis in malignant cells, inducing remission, maintaining remission, as chemotherapeutic agents, as well as for decreasing symptoms of cytopathic diseases and opportunistic infections that may accompany such diseases.

Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment and prevention of stroke and the sequelae of stroke. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools to treat or prevent stroke and the long term effects of stroke in mammalian subjects.

Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms, treatments, or sequelae of disease. The phorbol esters described are particularly useful in the treatment of neoplastic diseases and/or managing the side effects of chemotherapeutic and radiotherapeutic treatments of neoplastic diseases.

Abstract: A thermochromic pigment composition including compounds of formula (I): in which: X represents CHR2, O, OCO or CH?CH; Y represents O, COO, or OCOO; R1 represents H or (CH2)pCH3; R2 represents phenyl or H; m=12-18; n=0-14; p=12-18; and on the condition that, if n=0, X represents CHR2 or CH?CH. The thermochromic pigment compositions having compounds of formula (I), include thermochromic pigment microcapsules. The thermochromic pigment capsules are useable for thermochromic pigment compositions in ink which may be used writing instruments.

Abstract: The present invention aims to provide a means by which a cured product to be obtained has a low dielectric loss tangent and higher heat resistance. Specifically, provided are an active ester compound represented by chemical formula (1): (where in chemical formula (1), Ar1 is a substituted or unsubstituted first aromatic ring group, and each Ar2 is independently a substituted or unsubstituted second aromatic ring group, in which at least one of Ar1 and Ar2 has an unsaturated bond-containing substituent, and n is an integer of 2 or 3), a curable composition containing the active ester compound, and a cured product thereof.

Abstract: A process is provided for preparing ethylene amines of the formula NH2—(C2H4—NH—)pH wherein p is at least 2, or derivatives thereof wherein one or more units —NH—C2H4—NH— are present as a cyclic ethylene urea unit The process includes reacting an ethanolamine-functional compound OH—(C2H4—NH—)qH or HO—(C2H4—NH)q—C2H4—OH wherein q is at least 1, and an amine-functional compound NH2—(C2H4—NH—)rH wherein r is at least 1, in the presence of a carbon oxide delivering agent and water, with a molar ratio of water:carbon oxide delivering agent of from about 0.01:1 to about 2:1.

Abstract: The disclosure provides a synthesis method of 2,4,6-trifluorobenzylamine, belonging to the technical field of chemical synthesis. The synthesis method is characterized by comprising the following steps: (1) allowing pentachlorobenzonitrile as a raw material to undergo fluoridation reaction with a fluoridation agent based on 2,4,6-trifluoro-3,5-dichlorobenzonitrile as a solvent to obtain 2,4,6-trifluoro-3,5-dichlorobenzonitrile; (2) hydrogenating the obtained 2,4,6-trifluoro-3,5-dichlorobenzonitrile with hydrogen in the presence of organic carboxylic acid, based, on palladium carbon as a catalyst to obtain 2,4,6-trifluoro-3,5-dichlorobenzylamine; and (3) hydrogenating the obtained 2,4,6-trifluoro-3,5-dichlorobenzylamine with hydrogen in a solvent in the presence of a catalyst to obtain 2,4,6-trifluorobenzylamine.

Abstract: Disclosed herein are scavenging compounds and compositions useful in applications relating to the production, transportation, storage, and separation of crude oil and natural gas.

Abstract: The present disclosure provides industrially scalable methods of making (Z)-endoxifen or a salt thereof, crystalline forms of endoxifen, and compositions comprising them. The present disclosure also provides methods for treating hormone-dependent breast and hormone-dependent reproductive tract disorders.

Abstract: The present invention provides a compound having the structure: and use of the compound for inhibiting the growth of or killing

Abstract: Disclosed herein are novel antioxidant inflammation modulators, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds and compositions thereof are also provided.

Abstract: The present invention pertains to a process for preparing guanidino acetic acid (GAA) from cyanamide and glycine in alkaline process solution, in which anionic impurities are removed from the process solution by electrodialysis.

Abstract: The present invention addresses the problem of providing a method for producing purified methionine, the method being capable of preventing the caking of methionine. The present invention pertains to a method for producing purified methionine from crude methionine, the method comprising (1) a step for obtaining a wet cake of washed crude methionine, (2) a step for adjusting the pH of the wet cake, and (3) a step for drying the wet cake after the pH adjustment, wherein the pH of the wet cake after the pH adjustment is 5.2-6.1.

Abstract: Disclosed herein are compounds of formula (I) and therapeutic methods of treatment with compounds of formula (I), wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.

Abstract: The present invention relates to a method for purifying N-substituted maleimide. More specifically, the present invention, without performing a water washing process, enables to remove organic-acid-impurities which are difficult to remove through distillation because of having similar boiling points to the N-substituted maleimide compound by utilizing solubility of organic-acid-impurities in an organic solvent used in the preparing process of the maleimide compound, and thereby, without producing washing wastewater, ensuring removal efficiency of the organic-acid-impurities equal to or similar to an N-substituted maleimide compound subjected to a water washing process.

Abstract: The invention provides a combination comprising: (i) a compound of formula (Io): or a tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims; and (ii) a compound which is SGI-110 or a tautomer or a solvate or a pharmaceutically acceptable salt thereof. Also provided are pharmaceutical compositions containing the combinations and medical uses of the combinations.

Abstract: The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent device having a low driving voltage and/or a high luminous efficiency and/or a long lifespan can be provided, by comprising an organic electroluminescent compound according to the present disclosure.

Abstract: The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent device having a low driving voltage and/or a high luminous efficiency and/or a long lifespan can be provided, by comprising an organic electroluminescent compound according to the present disclosure.

Abstract: The present disclosure provides a compound used as the CPL material. The compound has a structure as shown in chemical formula I, in which L1 is selected from the group consisting of a substituted or unsubstituted C6-C30 arylene, C3-C30 heteroarylene, a substituted or unsubstituted C10-C60 fused arylene, and a substituted or unsubstituted C10-C60 fused heteroarylene; Ar1 is selected from the group consisting of a substituted or unsubstituted C6-C30 arylene, C3-C30 heteroarylene, a substituted or unsubstituted C10-C60 fused arylene, and a substituted or unsubstituted C10-C60 fused heteroarylene; n is 1 or 2, and when n is 2, the two Ar1 are identical or different; R1, R2, R3 and R4 are each independently selected from the group consisting of hydrogen, and a substituted or unsubstituted aryl or fused aryl, R1 and R2 are optionally bonded to form a ring, and R3 and R4 are optionally bonded to form a ring.

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.

Abstract: A process for producing an organic compound using a flow reactor for a first reaction in which a raw material liquid A and a raw material liquid B are mixed, and reacted in a reactor unit, and a flow reactor for a second reaction in which a first reaction solution discharged from the flow reactor for the first reaction and a raw material liquid C are mixed, and reacted in a reactor unit, wherein the raw material liquid A is a solution in which triphosgene and/or diphosgene is dissolved, wherein the raw material liquid B is a nitrogen-containing organic compound or a solution thereof, wherein the raw material liquid C is a reaction substrate having a functional group capable of reacting with phosgene, or a solution containing the reaction substrate, and wherein a product of the first reaction is phosgene.

Abstract: This invention is related to the field of PCSK9 biology and the composition and methods of use of small organic compounds as ligands for modulation of PCSK9 biological activity. In particular, the invention provides compositions of small organic compounds that modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9. Binding these small organic compound ligands to PCSK9 alters the conformation of the protein, modifying the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol. High LDL-cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunction; thus, there is also utility for small organic compound ligands that can raise LDL levels.

Abstract: A method of treating a retinal disease that leads to photoreceptor loss or outer-retina degeneration, includes administering a compound of formula (Ia) or a pharmaceutically acceptable salt thereof to a patient having the retinal disease so as to be delivered to an eye of the patient in an amount effective to treat the retinal disease: wherein A is an 5-oxazolyl residue or a pyridine-4-yl residue, R1 is selected from the group consisting of methoxy, fluoro and chloro; R2, R3, R4, R5 and R6 of the phenyl ring B are independently from each other selected from the group consisting of hydrogen, a linear or branched alkyl having 1 to 4 carbon atoms, trifluoromethyl, 2,2,2-trifluoroethyl, methylsulfanyl, ethylsulfanyl, methylsulfonyl, ethylsulfonyl, difluoromethoxy, trifluoromethoxy, fluoro, bromo, chloro, methoxy, ethoxy, propoxy, butoxy, hydroxy and amino; and at least two of R2, R3, R4, R5 and R6 are hydrogens.

Abstract: The invention relates to benzimidazole derivatives of the general formula I, and the use of the compounds of the present invention for the treatment and/or prevention of hyperproliferative or infectious diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.

Abstract: The present disclosure discloses compounds capable of modulating the activity of ?-amino-?-carboxymuconic acid semialdehyde decarboxylase (ACMSD), which are useful for the prevention and/or the treatment of diseases and disorders associated with defects in NAD+ biosynthesis, e.g., metabolic disorders, neurodegenerative diseases, chronic inflammatory diseases, kidney diseases, and diseases associated with ageing. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.

Abstract: The invention discloses a method for preparation of 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine by conversion of 5-nitro-2-propylthiopyrimidine-4,6-diol with phosgene in the presence of DMF.

Abstract: The present invention discloses unsaturated hydrocarbon pyrimidine thioether compounds of formula (I) and preparation method and application thereof, the compounds of formula (I) exhibit high insecticidal and acaricidal activity against adults, larvae and eggs of harmful mites and insects in the agriculture, civil use and animal technology fields, meanwhile, the compounds also exhibit good bactericidal activity, and can be widely applied as an insecticide, an acaricide and/or a bactericide in agriculture or other fields

Abstract: The present invention relates to an 18F-labelled compound, and a use thereof. The compound selectively binds to a prostate-specific membrane antigen (PSMA), and enables the acquisition of clear prostate cancer images in a short time when used in positron emission tomography (PET).

Abstract: The present invention provides an improved process for the preparation of Deferasirox of Formula-I substantially free from ‘hydrazino impurity’ by the condensation of 2-(2-hydrophenyl)-4H-1,3-benzoxazin-4-one of Formula-IV with 4-hydrazino benzoic acid of Formula-V in a polar solvent.

Abstract: The invention provides aryl indolinyl sulfonamide and related compounds, pharmaceutical compositions, methods of promoting ROR? activity and/or increasing the amount of IL-17 in a subject, and therapeutic uses of the indolinyl sulfonamide and related compounds, such as treating medical conditions in which activation of immune response is beneficial.

Abstract: Described herein is an hydrofluorocarboximidate of formula (I) where: RH is a linear or branched alkyl group comprising 1 or 2 carbon atoms and (a) Rf1 and Rf2 are independent-selected from a linear or branched perfluorinated alkyl group comprising 1-8 carbon atoms and optionally comprising at least one catenated atom selected from oxygen, nitrogen, or combinations thereof; or (b) Rf1 and Rf2 are connected to form a ring structure comprising a total of 4-8 carbon atoms and in addition to the nitrogen atom from the carboximidate the ring structure may optionally comprises at least one catenated atom selected from oxygen, nitrogen, or combinations thereof. A method of making the hydrofluorocarboximidate with improved yield is described as well as various uses for the hydrofluorocarboximidate of Formula (I).

Abstract: Provided in the present application are a sulfonyl amidine as represented by formula (I) as an indoleamine-2,3-dioxygenase inhibitor, and a preparation method therefor and the use thereof. The compound of formula (I) in the present application can be used as an indoleamine-2,3-dioxygenase inhibitor in the preparation of a drug for preventing and/or treating indoleamine-2,3-dioxygenase-mediated diseases.

Abstract: Provided herein is technology relating to amplification of nucleic acids and particularly, but not exclusively, to compositions and methods for doing improving the polymerase chain reaction and providing reagents for polymerase chain reaction with improved stability.

Abstract: Disclosed are methods for treating Vascular Leak Syndrome. Further disclosed are methods for treating vascular leakage due to inflammatory diseases, inter alia, sepsis, lupus, irritable bowel disease. Yet further disclosed are methods for treating renal cell carcinoma and melanoma. Still further disclosed are methods for reducing metastasis of malignant cells and/or preventing the proliferation of carcinoma cells via spreading due to vascular leakage.

Abstract: According to an example aspect of the present invention, there is provided a synthesis method for producing furoic acid from a monoacid containing five carbons in the presence of pressure, heat, solvent and catalyst.

Abstract: A heterocyclic compound, a composition including the heterocyclic compound, and an organic light-emitting device including the heterocyclic compound are disclosed. The heterocyclic compound is represented by Formula 1: wherein, X1, L1, a1, Ar1, R1 to R6, b3, b4, and b5 are described herein.